Clinical Trials Directory

Trials / Completed

CompletedNCT06220422

Assessment of a Procedure for Managing Oral Anticoagulants (NACO) in the Management of Fractures

Assessment the Benefit of a Service Procedure Management of NACO in the Treatment of Fractures of the Upper Extremity of the Femur

Status
Completed
Phase
Study type
Observational
Enrollment
127 (actual)
Sponsor
Hôpital NOVO · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to demonstrate that by allowing patients with an anticoagulant level less than 100 ng/ml to have their fracture managed surgically, will reduce the delay in surgery and therefore the complications associated. It will also demonstrate that there are no more complications with this new management than from remaining with a bleeding fracture.

Detailed description

Fracture of the upper extremity of the femur are constantly on the increase and represent a public health issue in a population with increasing life expectancy. In the majority of cases, this fracture requires rapid surgical treatment, ideally within 48 hours, before complications, associated with the supine position, appear. A prolonged surgical delay is responsible for multiple complications and increase mortality in a potentially comorbid and fragile population. Oral anticoagulants (NACOs) are now widely used in general population for cardiovascular diseases, such as non-valvular atrial fibrillation or thrombo-embolic events. Their activity and circulation rate are assessed by an Anti-Xa assay. The current recommendation for scheduled surgery is an assay with an anti-Xa activity of less than 50 ng/mL. The acquisition of this assay and the wait for a decrease in anti-Xa activity are currently a factor of lengthening the surgical delay leading to proposal a new dosage. By offering the possibility of surgical management with an anti-Xa activity of less than 100 ng/ml, the purpose is to demonstrate a reduction in surgical delay (less than 48 hours) and associated complications. One of the secondary purposes is also to demonstrate that there are no more intra and post-operative complications with this new protocol.

Conditions

Interventions

TypeNameDescription
PROCEDUREStandard Department procedure for managing direct-acting oral anticoagulantsStandard Department procedure for managing direct-acting oral anticoagulants (NACO \< 50 ng/mL) in the management of fractures before September 2021
PROCEDURENew Department procedure for managing direct-acting oral anticoagulantsNew Department procedure for managing direct-acting oral anticoagulants (NACO \< 100 ng/mL) in the management of fractures after September 2021

Timeline

Start date
2024-02-26
Primary completion
2024-04-10
Completion
2024-04-10
First posted
2024-01-24
Last updated
2024-06-12

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT06220422. Inclusion in this directory is not an endorsement.